PAOG Cannabis Drug Company Trends Bullish - $0.01 Breakout On Horizon?
October 21, 2020 -- InvestorsHub NewsWire -- via pennymillions/PAOG --
PAO Group, Inc. (USOTC:
PAOG) has a patent backed drug, RespRx, for treating lung
diseases to include a potential treatment for COVID-19.
PAOG - New Independent
CBD Research Appears To Support PAOG RespRx
PAOG announced yesterday that the company plans to release a new
key update this Friday, October 23, 2020, on its progress to
advance an investigational New Drug application (IND) with the Food
and Drug Administration (FDA).
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts,
Pink: KALY). RespRx is a cannabis treatment under development
for Chronic Obstructive Pulmonary Disease (COPD) derived from a
patented cannabis extraction method - U.S. Patent No. 9,199,960
entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT
MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD,
RespRx has demonstrated effecting significant increases in
respiration rate, tidal volume and inspiratory air flow rate.
Overall data from the evaluation demonstrated that RespRx can
significantly improve inspiratory lung functions in instances of
moderate pulmonary fibrosis.
Big FDA application news could see this sub penny make a major
breakout to over a penny.
Other stocks on the move include
AABB and SING.